Somatic alterations of the p53 tumor suppressor gene in vaccine-associated feline sarcoma

American Journal of Veterinary Research

Volumn 67, Issue 10, 2006, Pages 1766-1772

  Banerji, Nilanjana ^a,c   Kanjilal, Sagarika ^a,b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PROTEIN P53; RABIES VACCINE; VIRUS VACCINE;

ANIMAL TISSUE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CAT DISEASE; CONTROLLED STUDY; DISEASE FREE INTERVAL; DRUG INDUCED DISEASE; EXON; FEMALE; FOLLOW UP; GENE DELETION; GENE SEQUENCE; HETEROZYGOSITY LOSS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; POINT MUTATION; POSTOPERATIVE PERIOD; PREDICTION; RABIES; RHINOTRACHEITIS; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOFT TISSUE SARCOMA; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; VACCINATION;

ANIMALS; CAT DISEASES; CATS; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, P53; MALE; POLYMORPHISM, GENETIC; SARCOMA; VACCINES;

ANIMALIA; FELIDAE;

EID: 33750203397     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.67.10.1766     Document Type: Article

References (40)

1. Hendrick MJ, Goldschmidt MH. Do injection site reactions induce fibrosarcomas in cats (lett)? J Am Vet Med Assoc 1991;199:968.
2. Hendrick MJ, Goldschmidt MH, Shofer FS, et al. Postvaccinal sarcomas in the cat: epidemiology and electron probe microanalytical identification of aluminum. Cancer Res 1992;52:5391-5394.
3. Esplin DG, McGill LD, Meininger AC, et al. Postvaccination sarcomas in cats. J Am Vet Med Assoc 1993;202:1245-1247.
4. Kass PH, Barnes WG Jr, Spangler WL, et al. Epidemiologic evidence for a causal relation between vaccination and fibrosarcoma tumorigenesis in cats. J Am Vet Med Assoc 1993;203:396-405.
5. Hendrick MJ, Shofer FS, Goldschmidt MH, et al. Comparison of fibrosarcomas that developed at vaccination sites and at nonvaccination sites in cats: 239 cases (1991-1992). J Am Vet Med Assoc 1994;205:1425-1429.
6. Doddy FD, Glickman LI, Glickman NW et al. Feline fibrosarcomas at vaccination sites and non-vaccination sites. J Comp Pathol 1996;114:165-174.
7. Lester S, Clemett T, Burt A. Vaccine site-associated sarcomas in cats: clinical experience and a laboratory review (1982-1993). J Am Anim Hosp Assoc 1996;32:91-95.
8. Coyne MJ, Reeves NCP, Rosen DK. Estimated prevalence of injection-site sarcomas in cats during 1992. J Am Vet Med Assoc 1997;210:249-251.
9. Wise JK, Yang JJ. Veterinary service market for companion animals, 1992. Part II: veterinary service use and expenditures. J Am Vet Med Assoc 1992;201:1174-1176.
10. Hendrick MJ, Brooks JJ. Post-vaccinal sarcomas in the cat: histology and immunohistochemistry. Vet Pathol 1994;31:126-129.
11. Madewell BR, Griffey SM, McEntee MC, et al. Feline vaccine-associated fibrosarcoma: an ultrastructural study of 20 tumors (1996-1999). Vet Pathol 2001;38:196-202.
12. Mauldin GN. Soft tissue sarcomas. Vet Clin North Am Small Anim Pract 1997;27:139-147.
13. Ogilvie GK, Moore AS. Vaccine associated sarcomas in cats. In: Ogilvie GK, Moore AS, eds. Managing the veterinary cancer patient. Trenton, NJ: Veterinary Learning Systems Co Inc, 1995;515-518.
14. Macy DW. Current understanding of vaccination site-associated sarcomas in the cat. J Feline Med Surg 1999;1:15-21.
15. Hershey EA, Sorenmo KU, Hendrick MJ, et al. Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases (1986-1996). J Am Vet Med Assoc 2000;216:58-61.
16. Davidson EB, Gregory CR, Kass PH. Surgical excision of soft tissue fibrosarcomas in cats. Vet Surg 1997;26:265-269.
17. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
18. Ogilvie GK, Moore AS. Soft tissue sarcomas. In: Ogilvie GK, Moore AS, eds. Feline oncology. Trenton, NJ: Veterinary Learning Systems Co Inc, 2001;429-440.
19. Vaccine-Associated Feline Sarcoma Task Force. Roundtable discussion: the current understanding and management of vaccine-associated sarcomas in cats. J Am Vet Med Assoc 2005;226:1821-1842.
20. Saiki RK, Gelfand DH, Stoffel S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988;239:487-491.
21. Okuda M, Umeda A, Matsumoto Y, et al. Molecular cloning and chromosomal mapping of feline p53 tumor suppressor gene. J Vet Med Sci 1993;55:801-805.
22. Mayr B, Schaffner G, Kurzbauer R, et al. Mutations in tumor suppressor gene p53 in two feline fibrosarcomas. Br Vet J 1995;151:707-713.
23. Cho Y, Gorina S, Jeffrey PD, et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-355.
24. Olivier M, Eeles R, Hollstein M, et al. The IARC TP53 database version R9 of July 2004: new online mutation analysis and recommendations to users. Hum Mutat 2002;19:607-614.
25. Kanjilal S, Strom SS, Clayman GL, et al. p53 mutations in nonmelanoma skin cancer of the head and neck: molecular evidence for field cancerization. Cancer Res 1995;55:3604-3609.
26. Vousden KH, Prives C. P53 and prognosis: new insights and further complexity. Cell 2005;120:7-10.
27. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci USA 1993;90:10914-10921.
28. Nambiar PR, Jackson ML, Ellis JA, et al. Immunohistochemical detection of tumor suppressor gene p53 protein in feline injection site-associated sarcomas. Vet Pathol 2001;38:236-238.
29. Rieske P, Bartkowiak JK, Szadowska AM, et al. A comparative study of P53/ MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas. J Exp Clin Cancer Res 1999;18:403-416.
30. Kim E, Gunther W, Yoshizato K, et al. Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1. Oncogene 2003;22:7716-7727.
31. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545.
32. Okegawa T, Li Y, Pong RC, et al. Cell adhesion proteins as tumor suppressors. J Urol 2002;167:1836-1843.
33. Cohen M, Wright JC, Brawner WR, et al. Use of surgery and electron beam irradiation, with or without chemotherapy, for treatment of vaccine-associated sarcomas in cats: 78 cases (1996-2000). J Am Vet Med Assoc 2001;219:1582-1589.
34. Kobayashi T, Hauck ML, Dodge R, et al. Preoperative radiotherapy for vaccine associated sarcoma in 92 cats. Vet Radiol Ultrasound 2002;43:473-479.
35. Hauck M. Feline injection site sarcomas. Vet Clin North Am Small Anim Pract 2003;33:553-557.
36. Williams LE, Banerji N, Klausner JS, et al. Establishment of two vaccine-associated feline sarcoma cell lines and determination of in vitro chemosensitivity to doxorubicin and mitoxantrone. Am J Vet Res 2001;62:1354-1357.
37. Banerji N, Li X, Klausner JS, et al. Evaluation of in vitro chemosensitivity of vaccine-associated feline sarcoma cell lines to vincristine and paclitaxel. Am J Vet Res 2002;63:728-732.
38. Novosad CA. Principles of treatment for vaccine-associated sarcomas. Clin Tech Small Anim Pract 2003;18:115-117.
39. Skubitz KM, Skubitz AP. Characterization of sarcomas by means of gene expression. J Lab Clin Med 2004;144:78-91.
40. Cormier JN, Pollock RE. Soft tissue sarcoma. CA Cancer J Clin 2004;54:94-109.